Delaware Clinical and Translational Research ACCEL Program

摘要-总体 该提案是对用于临床和转化研究的IDEA计划基础设施的竞争性更新 （IDEA-CTR）（U 54）补助金最初于2013年9月授予。该项目名为“特拉华州CTR ACCEL” 计划，因此目前已完成四年的资金在此申请时。的总体目标 ACCEL计划仍然是提供关键组成部分，使战略领域的增长，以改善健康的 特拉华州和全国的公民。我们的联盟目前由四个合作伙伴组成：特拉华州大学 （UD）-牵头机构;杜邦儿童医院是内穆尔儿童卫生系统的一部分（Ne- mours）;克里斯蒂娜护理医院系统（CCHS），特拉华州最大的医疗保健系统;以及 南卡罗来纳州医科大学（MUSC），我们的州外IDEA合作伙伴。在这次竞争性更新中，我们将 扩大我们的联盟，包括特拉华州州立大学（DSU），美国历史上的黑人，公立大学- 位于特拉华州的多佛。特拉华州是CTR赠款的理想州，因为它代表了整个美国， 紧凑型特拉华州的人口（约95万）反映了美国城市与农村人口的比例， 族裔/种族多样性，22%为非洲裔美国人，69%为高加索人，8%为西班牙裔，3%为亚洲人，1%为美洲原住民。 成人（CCHS）和儿科（Nemours）医院系统占主导地位，为至少85%的居民提供服务 提供了一个独特的机会，将特拉华州作为一个模型，研究医疗保健如何 这些变化可能影响人口健康。与ACCEL计划目前享有的强有力支持类似，部分- 合作机构和国家再次同意提供超过830万美元的资金，以支持ACCEL相关活动， 关系的ACCEL计划的结构和活动在这次竞争性更新中进行了修改。关于ACCEL 计划现在只包括行政核心和五个必要的关键组成部分活动。此外，本发明还提供了一种方法， 基于经验教训、发现的机遇和取得的成功，我们已经做出了实质性的令人振奋的改变 ACCEL计划的每个组成部分。ACCEL计划的总体具体目标是：1）提供操作- 提高优秀调查人员进行令人兴奋和有影响力的调查的能力 在需要和机会的领域的临床和转化研究计划。2)招募、培训和发展临床- 科学家，科学家和工程师谁将开发创新，竞争力，跨学科和跨机构的临床， 学术和翻译研究团队，以及3）扩大和加强示范社区参与外展研究 与国家和其他利益相关者合作，促进不同人口的健康和福祉的计划， 特拉华人 ACCEL计划的领导层为我们在过去四年中创建的强大基础感到自豪 并期待着继续发展临床和转化研究计划，以解决一些 最重要的医疗保健需求特拉华州和所有美国人。

Abstract—Overall This proposal is a competitive renewal of the IDeA Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54) grant originally awarded in September 2013. The program, titled the Delaware CTR ACCEL Program, has thus currently completed four years of funding at the time of this application. The overall goal of the ACCEL Program remains to provide the key components to allow growth in strategic areas to improve the health of the citizens of Delaware and the nation. Our consortium currently consists of four partners: University of Delaware (UD)—the lead institution; A.I. DuPont Hospital for Children, a part of the Nemours Children’s Health System (Ne- mours); Christiana Care Hospital System (CCHS), the largest health care sys-tem in the state of Delaware; and the Medical University of South Carolina (MUSC), our out-of-state IDeA partner. In this competitive renewal, we will expand our consortium to include Delaware State University (DSU), an American historically black, public univer- sity located in Dover, Delaware. Delaware is an ideal state for a CTR grant as it represents the whole of the USA in a compact form. The population of Delaware (~950,000) mirrors the US population in urban-to-rural citizen ratio and ethnic/racial diversity, with 22% African American, 69% Caucasian, 8% Hispanic, 3% Asian and 1% Native American. The dominance of adult (CCHS) and pediatric (Nemours) hospital systems, which serve at least 85% of the residents of the state, provides a unique opportunity to treat the state of Delaware as a model for examining how healthcare changes can impact population health. Similar to the strong support the ACCEL Program currently enjoys, the part- nering institutions and the State have again agreed to provide over $8.3 M in funds to support ACCEL related activi- ties. The structure and activities of the ACCEL Program have been modified in this competitive renewal. The ACCEL Program now only includes the Administrative Core and the five required key component activities. In addition, based on lessons learned, opportunities discovered, and success achieved, we have made substantive exciting changes to every component of the ACCEL Program. The Overall Specific Aims for the ACCEL Program are to: 1) Provide op- portunities and infrastructure that enhance the ability of outstanding investigators to conduct exciting and impactful clinical and translational research programs in areas of need and opportunity. 2) Recruit, train, and develop clini- cians, scientists, and engineers who will develop innovative, competitive, interdisciplinary, and interinstitutional clin- ical and translational research teams, and 3) Expand and enhance model community engagement outreach research programs that work with the State and other stakeholders to promote health and wellness to a diverse population of Delawareans. The leadership of the ACCEL program is proud of the strong foundation we have created over the past four years and looks forward to continuing to grow clinical and translational research programs that address some of the most important health care needs of Delawareans and all Americans.